© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
Blood Glucose Levels in T2D: 42 Factors that Make A Difference
November 05, 2025
These 42 factors that affect blood glucose are in categories including food, activity, and biological influences. Perfect information to share with your patients with T2D.
Tirzepatide Found to Lower A1C, BMI in Children and Adolescents with T2D: Daily Dose
November 05, 2025
Your daily dose of the clinical news you may have missed.
FAQs on Cardiac Rehab in Women for Primary Care Clinicians
November 05, 2025
Women experience greater CR mortality benefits than men yet have 36% lower enrollment. New AHA statement addresses barriers across the care continuum.
Lisa Larkin, MD: Elinzanetant Offers a “Game-Changing” Option for Menopause Care in Primary Care
November 05, 2025
Lisa Larkin, MD, discusses how elinzanetant may change menopause management for women who can’t use hormone therapy and what PCPs need to know.
Facility-Based CRC Screening Nearly 10-Fold Higher in 45- to 49-Year-Olds After Guideline Changes
November 05, 2025
Colorectal cancer screenings for 45- to 49-year-olds surge nearly tenfold after new guidelines, highlighting significant shifts in public health practices.
FDA Approves New Treatment for Acromegaly: Daily Dose
November 04, 2025
Your daily dose of the clinical news you may have missed.
Perimenopausal Brain Fog: A Frequent Complaint That Needs a Compassionate Response, Says Marla Shapiro, CM, CCFP, MHSc
November 04, 2025
"If you don't know where your keys are, that's fine." Shapiro's memorable analogy helps distinguish perimenopause brain fog from serious cognitive concerns.
GLP-1 Receptor Agonist GI Safety Comparable Within the Class, But Exceeds SGLT-2 Inhibitor Risk
November 04, 2025
The real-world study of 200,000+ adults found no GI safety differences among 3 GLP-1 drugs for T2D, however SGLT-2 inhibitors are safer for motility issues.
Tezepelumab Achieves Dual Benefit in Severe Asthma, Improving Control with Reduced Steroid Dependence
November 04, 2025
WAYFINDER: 90% of steroid-dependent severe asthma patients reduced to ≤5mg daily on tezepelumab. Well-controlled asthma increased from 3% to 27% at 52 weeks.
EPIC-Norfolk Study Supports Universal Screening for Three Cardiovascular Biomarkers
November 04, 2025
Three-biomarker panel independently predicted cardiovascular events over 20 years in European cohort, with highest risk when all 3 were elevated.